Aligos Therapeutics, Inc. (ALGS)
- Previous Close
0.8180 - Open
0.8180 - Bid 0.7471 x 300
- Ask 0.8324 x 100
- Day's Range
0.7700 - 0.8341 - 52 Week Range
0.5390 - 1.3800 - Volume
110,399 - Avg. Volume
397,098 - Market Cap (intraday)
59.173M - Beta (5Y Monthly) 2.34
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3600 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.00
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
www.aligos.comRecent News: ALGS
Performance Overview: ALGS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALGS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALGS
Valuation Measures
Market Cap
59.17M
Enterprise Value
-65.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.24
Price/Book (mrq)
0.64
Enterprise Value/Revenue
-4.21
Enterprise Value/EBITDA
0.77
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.63%
Return on Equity (ttm)
-89.48%
Revenue (ttm)
15.53M
Net Income Avi to Common (ttm)
-87.68M
Diluted EPS (ttm)
-1.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
135.7M
Total Debt/Equity (mrq)
12.10%
Levered Free Cash Flow (ttm)
-45.91M